ArticleClinical rheumatology2026
Epigenetic alterations in WDFY4 DNA methylation are linked to immunoinflammatory processes in rheumatoid arthritis: insights from a case-control study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveThis study examines the relationship between WDFY4 gene DNA methylation and clinical characteristics of rheumatoid arthritis (RA) through peripheral blood analysis.
methodsPeripheral blood samples from 150 RA patients and 150 healthy controls were analyzed via targeted methylation sequencing. Generalized linear regression assessed associations between WDFY4 methylation haplotypes, CpG sites, and clinical markers, with adjustment for potential confounders.
resultsRA patients exhibited significantly reduced overall WDFY4 methylation levels compared to controls (0.865 ± 0.053 vs. 0.882 ± 0.043) (FDR P = 0.0088), with six specific CpG sites showing marked hypomethylation (FDR P < 0.05). Among the 22 identified haplotypes, five differed significantly between groups. Negative correlations were observed between WDFY4 methylation and anti-CCP antibodies (ACPA), rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).
conclusionsWDFY4 methylation may critically influence RA pathogenesis and immunoinflammatory responses. Integrating WDFY4 methylation data with environmental factors, inflammatory markers (CRP/ESR), and autoantibodies (ACPA/RF) could enhance the understanding of RA pathophysiology and potentially aid in subgroup stratification. Key Points • Targeted methylation sequencing revealed significant WDFY4 hypomethylation at specific CpG sites in RA patients versus controls. • WDFY4 methylation levels negatively correlated with RA autoantibodies and inflammatory markers, indicating its potential role in disease mechanisms. • Integrating WDFY4 methylation with clinical data improved RA and comorbidity diagnosis, with an AUC of 0.844 for predicting pulmonary fibrosis, highlighting its novel discriminative potential.
Indexed as
Identifiers
41965494What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.